Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

MicroRNA Biogenesis Pathway Genes Are Deregulated in Colorectal Cancer.

Vychytilova-Faltejskova P, Svobodova Kovarikova A, Grolich T, Prochazka V, Slaba K, Machackova T, Halamkova J, Svoboda M, Kala Z, Kiss I, Slaby O.

Int J Mol Sci. 2019 Sep 10;20(18). pii: E4460. doi: 10.3390/ijms20184460.

2.

Communication with cancer patient.

Halámková J, Sláma O, Krákorová DA, Demlová R, Kuře J.

Vnitr Lek. 2019 Spring;65(5):359-362.

PMID:
31163969
3.

MiR-215-5p is a tumor suppressor in colorectal cancer targeting EGFR ligand epiregulin and its transcriptional inducer HOXB9.

Vychytilova-Faltejskova P, Merhautova J, Machackova T, Gutierrez-Garcia I, Garcia-Solano J, Radova L, Brchnelova D, Slaba K, Svoboda M, Halamkova J, Demlova R, Kiss I, Vyzula R, Conesa-Zamora P, Slaby O.

Oncogenesis. 2017 Dec 4;6(11):399. doi: 10.1038/s41389-017-0006-6.

4.

Efficacy of bevacizumab and chemotherapy in the first-line treatment of metastatic colorectal cancer: broadening KRAS-focused clinical view.

Bencsikova B, Bortlicek Z, Halamkova J, Ostrizkova L, Kiss I, Melichar B, Pavlik T, Dusek L, Valik D, Vyzula R, Zdrazilova-Dubska L.

BMC Gastroenterol. 2015 Mar 24;15:37. doi: 10.1186/s12876-015-0266-6.

5.

Efficacy and toxicity of bevacizumab on combination with chemotherapy in different lines of treatment for metastatic colorectal carcinoma.

Kiss I, Bortlicek Z, Melichar B, Poprach A, Halamkova J, Vyzula R, Dusek L, Buchler T.

Anticancer Res. 2014 Feb;34(2):949-54.

PMID:
24511038
6.

Clinical relevance of uPA, uPAR, PAI 1 and PAI 2 tissue expression and plasma PAI 1 level in colorectal carcinoma patients.

Halamkova J, Kiss I, Pavlovsky Z, Jarkovsky J, Tomasek J, Tucek S, Hanakova L, Moulis M, Cech Z, Zavrelova J, Penka M.

Hepatogastroenterology. 2011 Nov-Dec;58(112):1918-25. doi: 10.5754/hge10232.

PMID:
22234062

Supplemental Content

Loading ...
Support Center